Using a structured approach to assess whether your Rx product is ready for a switch to OTC in the EU
This article was originally published in SRA
Pharmaceutical companies have many factors to consider in deciding whether a switch to over the counter is the right strategy for their products. Rosalind Cox recommends a structured approach.
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.